Abstract
Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.
| Original language | English |
|---|---|
| Pages (from-to) | 376-382 |
| Number of pages | 7 |
| Journal | Molecular and Clinical Oncology |
| Volume | 11 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Oct 2019 |
Fingerprint
Keywords
- Low skeletal muscle mass
- Ovarian cancer
- Prognostic factor
- Psoas area
- Psoas major volume
- Skeletal muscle area
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer. / Matsubara, Yuko; Nakamura, Keiichiro; Matsuoka, Hirofumi; Ogawa, Chikako; Masuyama, Hisashi.
In: Molecular and Clinical Oncology, Vol. 11, No. 4, 10.2019, p. 376-382.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Pre-treatment psoas major volume is a predictor of poor prognosis for patients with epithelial ovarian cancer
AU - Matsubara, Yuko
AU - Nakamura, Keiichiro
AU - Matsuoka, Hirofumi
AU - Ogawa, Chikako
AU - Masuyama, Hisashi
PY - 2019/10
Y1 - 2019/10
N2 - Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.
AB - Low skeletal muscle mass (sarcopenia) is an important prognostic risk factor for the outcome of a variety of cancer types. The current study investigated whether skeletal muscle area (SMA), psoas area (PA) and psoas major volume (PV) are associated with progression-free survival (PFS) and overall survival (OS) in patients with epithelial ovarian cancer (OC). A total of 92 OC patients were enrolled in the present study. Pre-treatment with SMA and PA was assessed using computed tomography (CT) and PV was calculated using a three-dimensional-CT (3D-CT). The clinical factors associated with sarcopenia and prognosis were retrospectively evaluated. For all patients, the median PFS and OS were 19 and 32 months, respectively. Patients exhibiting lower PV (<195.6 cm3) had significantly poorer PFS and OS compared with patients exhibiting higher PV (≥195.6 cm3; P=0.018 and P=0.006), while those with low SMA (<92.92 cm2) had significantly worse OS than patients with higher SMA (≥92.92 cm2; P=0.030). PV was also demonstrated to be superior to SMA and PA in prognosis prediction. PV by 3D-CT can serve as an indicator of poor prognosis in patients with OC.
KW - Low skeletal muscle mass
KW - Ovarian cancer
KW - Prognostic factor
KW - Psoas area
KW - Psoas major volume
KW - Skeletal muscle area
UR - http://www.scopus.com/inward/record.url?scp=85073392966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073392966&partnerID=8YFLogxK
U2 - 10.3892/mco.2019.1912
DO - 10.3892/mco.2019.1912
M3 - Article
AN - SCOPUS:85073392966
VL - 11
SP - 376
EP - 382
JO - Molecular and Clinical Oncology
JF - Molecular and Clinical Oncology
SN - 2049-9450
IS - 4
ER -